Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies. - Wikidata - wikimedia - TriplyDB

Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies.

Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies.

http://www.wikidata.org/entity/Q27692050

about

Recent Updates on the Management of Medullary Thyroid Carcinoma The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria.A systematic review and meta-analysis of the risk of diarrhea associated with vandetanib treatment in carcinoma patients.Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer.Development of Photoonycholysis with Vandetanib Therapy.Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy.Selective use of vandetanib in the treatment of thyroid cancer.Surgical management of medullary thyroid carcinoma.A rare case of late-onset lichenoid photodermatitis after vandetanib therapy.The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer.

P2860

Q28066911-D1255832-3460-4C53-92EA-080998CF98FE Q35318395-102DE089-A681-4BC2-818D-685B00F4D86C Q36068707-3DC73D40-A208-444F-AA29-CCAE0783DCCB Q37387829-E60D0B13-FC69-4C63-9E74-8D9CCEC44340 Q37604797-0BC55E56-EBA6-48FE-BB69-B4A96AAE24E9 Q38286128-C2CEF53D-F541-4A84-9C36-649934921B45 Q38546474-0B150418-9E8B-450B-B4BC-BA39FE0A0886 Q38837195-4174EF7E-1B4F-493A-9EA2-165A3F4A35AB Q39534408-D9C76459-D974-4428-A694-3E3348C68A19 Q41470815-41E7393D-D4CF-4998-B30D-B15C69B1E1B0 Q47161687-C1F0B2A0-B94C-46B3-90C8-2532E7393FD9

P2860

Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies.

http://www.wikidata.org/entity/Q27692050

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Vandetanib in advanced medulla ...... e event management strategies.

@ast

Vandetanib in advanced medulla ...... e event management strategies.

@en

Vandetanib in advanced medulla ...... e event management strategies.

@nl

type

label

Vandetanib in advanced medulla ...... e event management strategies.

@ast

Vandetanib in advanced medulla ...... e event management strategies.

@en

Vandetanib in advanced medulla ...... e event management strategies.

@nl

prefLabel

Vandetanib in advanced medulla ...... e event management strategies.

@ast

Vandetanib in advanced medulla ...... e event management strategies.

@en

Vandetanib in advanced medulla ...... e event management strategies.

@nl

P1433

Q27692050-764BC520-F339-47DC-9985-715D14FFC720

P1476

Q27692050-5EE324BF-325D-4929-9176-18F3B55144EA

P2093

Q27692050-3047A49B-FBAF-4672-8717-6DD7C0C9284D

Q27692050-349E7126-2422-40CC-ABF4-5764B0700024

Q27692050-4EB99894-AD81-4A19-914A-8FCC598DDEAE

Q27692050-51F7E828-4CB8-436C-95D7-D4DA8AF5A15A

Q27692050-5E6DEB30-DDE0-40D0-ABB0-945F082463FE

Q27692050-BF93B0E5-EF5A-4ECC-A9E9-851CF9C770C6

Q27692050-D0FFEF65-7FDF-41F6-A7DF-032ACED650CB

Q27692050-EED480A1-59BB-4C2C-B2AA-05E067D719BF

Q27692050-F6C92BF5-6A13-4FF3-86CF-E6D7DBD3BC53

P2860

Q27692050-0C7B36A7-D6CA-471E-A837-E93E043808EC

Q27692050-0E05EB06-A57A-475D-8943-7A93EADD80A1

Q27692050-17B7A3E6-F511-4A70-9A35-10FBB874BAB1

Q27692050-20F76726-EC1A-4F7D-A574-DD998A454228

Q27692050-26ECA5DB-2358-4EF7-AB1C-558B6410AEC5

Q27692050-26F7A54C-EAB2-4DBC-9DCD-9F79189AA1C1

Q27692050-2867A087-B358-4C00-AC00-84E2C4C45443

Q27692050-29A1D173-5D16-476F-8465-4D4667FC2DE8

Q27692050-39A79865-3F56-41A7-AC90-290D0BFB343E

Q27692050-437E07A9-BB67-4A54-88B9-110B8D716CAA

P2888

Q27692050-00B8CB2E-6948-435B-83F2-3ECB03709491

P304

Q27692050-AC5274DE-79AA-4C42-8908-8AC212B0857A

P31

Q27692050-C66F07A4-922C-4A62-9B60-26E94DC39A8E

P3181

Q27692050-E51613F4-8F5D-4DE7-951F-CB1860C2ABB9

P356

Q27692050-89745F00-6307-4651-B231-E70095CD24DA

P407

Q27692050-30A83846-678C-4DCF-A20C-822BA4FDD520

P433

Q27692050-A89AE92F-BF4F-4F6C-B8C7-AA51A666644D

P478

Q27692050-E250A1D5-D277-47AB-B68D-436790FEC434

P50

Q27692050-F84B6BD0-F8CB-4568-8CF1-BA78C780DC83

P577

Q27692050-7D1B0993-2A6B-432F-B469-2FE8AE01EAE3

P5875

Q27692050-23B56123-C9BF-481D-A732-F4BC58C00BC2

P6179

Q27692050-760BD68F-52F4-43BD-91DA-FF7B70C9313D

P698

Q27692050-35D300BF-70B6-4823-B420-CAFA0157B5A0

P921

Q27692050-54F96547-EE22-4AF9-883E-780A26448E89

Q27692050-89F5BF57-BC48-46E9-84D1-30F02F9AD0E5

P932

Q27692050-D2FAEB33-9499-461F-BDC8-4A0A322EF674

P3181

P356

S12325-013-0069-5

P1433

Advances in Therapy

P1476

Vandetanib in advanced medulla ...... se event management strategies

@en

P2093

Caroline Robert

http://www.w3.org/2001/XMLSchema#string

Enrique Grande

http://www.w3.org/2001/XMLSchema#string

Jaume Capdevila

http://www.w3.org/2001/XMLSchema#string

Jose L Zamorano

http://www.w3.org/2001/XMLSchema#string

Kate Newbold

http://www.w3.org/2001/XMLSchema#string

Martin Schlumberger

http://www.w3.org/2001/XMLSchema#string

Michael C Kreissl

http://www.w3.org/2001/XMLSchema#string

Sebastiano Filetti

http://www.w3.org/2001/XMLSchema#string

Walter Reinisch

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacokinetics of vandetanib: three phase I studies in healthy subjects

Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.

Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer

ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.

Effect of intravenous ondansetron on QT interval prolongation in patients with cardiovascular disease and additional risk factors for torsades: a prospective, observational study.

Effects of thyroid hormone on the cardiovascular system.

Stevens-johnson syndrome induced by vandetanib.

Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials.

P2888

s12325-013-0069-5

P304

945-966

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

659271

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S12325-013-0069-5

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Lærke K Tolstrup

P577

2013-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258702281

http://www.w3.org/2001/XMLSchema#string

P6179

1019396808

http://www.w3.org/2001/XMLSchema#string

P698

24249433

http://www.w3.org/2001/XMLSchema#string

P921

heterocyclic compound

P932

3898148

http://www.w3.org/2001/XMLSchema#string